Caroline Rauffenbart

About Caroline Rauffenbart

I work in competitive R&D intelligence within the cardio-renal-metabolic disease research group at Boehringer Ingelheim. I analyze scientific, clinical, patent, and business developments across discovery, preclinical, and clinical-stage programs and translate them into strategic implications for research and pipeline planning.Trained as a translational neuroscientist (PhD, Columbia University), I bring a mechanistic lens to evaluating emerging therapeutic approaches. I am particularly interested in how early scientific and competitive signals shape portfolio strategy and partnership decisions in biopharma.My doctoral research in the Javitch Lab focused on receptor pharmacology and intracellular signaling dynamics, using BRET-based approaches to characterize drug-induced effector recruitment to metabotropic glutamate receptors (mGluRs). I also investigated the molecular basis of dopamine receptor signaling cascades; I studied the divergent intracellular pathways downstream of the dopamine \"D2R\" receptor and their effects on brain activity and behavior. Recipient of the NIH/NIDA Ruth L. Kirschstein F31 fellowship award. Project summary: https://reporter.nih.gov/project-details/10••••22

Experience

1. Competitive Intelligence Analyst

   Boehringer Ingelheim

   Sep 2024 — Present

   Develops in-depth competitive landscape analyses for early-stage CRM programs, assessing differentiation, mechanistic risk, and emerging external threats to inform asset positioning and research strategy-Monitors and interprets external innovation signals, including patents, preclinical disclosures, publications, clinical data releases, financing events, and partnership activity-Authors and distributes a monthly Kidney Disease strategic intelligence briefing to research stakeholders that provides actionable insights and emerging opportunities based on the most recent early-stage scientific and business developments-Provides forward-looking implications and recommendations for internal portfolio discussions, and presents structured analyses to research and portfolio leadership.

Education

• Bard High School Early College

  Associate of Arts (A.A.), Liberal Arts and Sciences

  2007 — 2011

• The University of North Carolina at Chapel Hill

  Bachelor of Science (BS), Biology, Chemistry

  2011 — 2014

• Columbia University

  Master of Arts - MA, Pharmacology & Molecular Signaling

  2017 — 2019

• Columbia University

  Doctor of Philosophy - PhD, Molecular Pharmacology and Therapeutics

  2017 — 2024

• Columbia University

  Master of Philosophy - MPhil, Pharmacology & Molecular Signaling

  2021

Skills

• Spss
• Research
• Laboratory
• Clinical Development
• Qualitative Research
• Mouse